US3085940A - Nu, nu'-methylene-bis-amides for the suppression of tumors - Google Patents

Nu, nu'-methylene-bis-amides for the suppression of tumors Download PDF

Info

Publication number
US3085940A
US3085940A US27488A US2748860A US3085940A US 3085940 A US3085940 A US 3085940A US 27488 A US27488 A US 27488A US 2748860 A US2748860 A US 2748860A US 3085940 A US3085940 A US 3085940A
Authority
US
United States
Prior art keywords
tumors
methylene
bis
remission
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US27488A
Inventor
Andrew S Tomcufcik
Stuart D Willson
Adolph W Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US27488A priority Critical patent/US3085940A/en
Priority to FR847668A priority patent/FR1202M/en
Priority to GB44723/60A priority patent/GB905186A/en
Priority to BE598856A priority patent/BE598856A/en
Application granted granted Critical
Publication of US3085940A publication Critical patent/US3085940A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups

Definitions

  • This invention relates to novel compositions of matter for the treatment of malignant growths in mammals.
  • the compounds of the present invention may be readily prepared by the interaction of 2 moleslof B-buteneamide or 2 moles of the appropriate '3-halopropionamide with 1 mole of formalhyde in the presence of a strong acid. Ordinarily, the reaction is carried out for a period of time ranging from a 'few minutes to an hour or more and at a temperature ranging from 30 C. to 100 C.
  • the appropriate nitrile may be substituted for the 3-buteneamide or 3-halopropionamide as the starting material.
  • hydrolytic conditions are employed so that the nitrile is hydrolyzed to its corresponding amide.
  • alternate forms of formaldehyde such as paraformaldehyde may also be used.
  • the desired product may then be recovered from the reaction mixture by concentration or by dilution with water.
  • the compounds of the present invention were tested against the tumors Sarcoma 180, lymphosarcoma 6C HED and C H mammary adencarinoma 72 Tumors from donor mice were minced and the particles transplanted, using a trocar, and inserted subcutaneously into the axillary region of a C l-I inbred strain of mice. When the tumors had grown to a palpable size (5-14 days) depending on the particular tumor, the test mice were grouped according to tumor size and treatment was started. An exception was the lymphosarcoma 6C HED in which treatment was started 2 to 3 days after implant before tumors were palpable. Treatment was by daily intraperitoneal injection for 6 days. Tumor harvest was on the seventh day following the first treatment. The tumors were weighed after excision and the following activity ratio was determined.
  • the oral dose per day may vary from 5 to 500 mg. per kg. of body weight.
  • a divided dose may vary from 50 mg. to 5.0 g. and the frequency of administration may vary widely.
  • the activity of the compounds of the present invention against animal tumors presages a usefulness in the clinical remission of lymphomas and leukemia-s for periods of time that will vary with -difierent individuals.
  • the effectiveness o-tthe compounds of the present inven tion in causing the remission of tumors in human subjects has not yet been demonstrated.
  • the compounds of the present invention may be orally administered in any. of the usual dosage unit forms of pharmaceutical preparations. These may take the form of tablets, capsules, pills, powders orany other desirable form in the therapeutic quantities set forth above.
  • the dosage form may be for a single daily therapeutic dose or in smaller units for multiple doses or in larger units for division into single doses. It is understood that in addition to the therapeutic compound there may be present excipients, binders, fillers, and other therapeutically inert ingredients necessary in the formulation of pharmaceutical preparations.
  • the compounds of the present invention may also be administered parenterally by dissolving or suspending the compound in a parenterally suitable vehicle such as, for example, propylene glycol or polyethylene glycol, or by dissolving or suspending the compound in an aqueous solution of such vehicle.
  • a parenterally suitable vehicle such as, for example, propylene glycol or polyethylene glycol
  • Example 1 N, N'-METHYLENE-BIS-(s-BROMOPROPIONAMIDE) A solution of 8.3 g. of 37% tormaldehyde in 21 g. of concentrated sulfuric acid was added to 26.8 g. of 3- bromopropionit-rile at 35-40 C. After five hours the solution was poured onto ice and the crude product was removed by filtration. There was obtained 25 .0 g. (79% crude yield) of N,N-methylene-bis-(3-bromopropionamide). M.P. 184-186.5 C. Recrystallization from 80% acetone gave white crystals, M.P. 184.5-1-86.5 C.
  • Example 3 N,N' -METHYLENE-BIS- 3-BUTENEAMIDE
  • a solution of 8.1 g. of 37% formaldehyde in 21 g. of concentrated sulfuric acid was added dropwise to 13.4 g. of 3-butenenitrile at 15 C.
  • the resulting thick syrup was stored overnight at 25 C. and then poured onto ice.
  • the crude product was removed by filtration whereby there was obtained 10.7 g. (58% crude yield) of N,N'- methylene-bis-(3-buteneamide), M.P. 193-198 C.
  • Example 4 A mixture of parts of N,N-methylene bis-(3- bromopropionamide), 15 parts of starch, and 1 part of magnesium stearate was thoroughly blended and then screened through a 60 mesh screen. The resulting powder was tableted in an automatic tableting machine whereby suitable 500 mg. scored white tablets were obtained.
  • a therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to 50 g. of a compound having the general formula 0 R.( i-NHoHr-NH- iRl wherein R and R are the same and are selected from the group consisting of the allyl and 2-haloethyl radicals, and a solid pharmaceutical carrier.
  • a therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to 50 g. of N,N-methylene-bis- (3-bromopropionamide) and a solid pharmaceutical carrier.
  • a therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to g. of N,N'-methylene-bis- (3-iodopropionamide) and a solid pharmaceutical carrier.
  • a therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to 50 g. of N,N'-methylene-bis- (3-butenearnide) and a solid pharmaceutical carrier.
  • a method for causing the remission of tumors in mammals which comprises administering in dosage unit form from 5 mg. to 500 mg. per kg. of body weight per day of a compound of the formula:
  • a method for causing the remission of tumors in mammals which comprises administering in dosage unit form 'from 5 mg. to 500 mg. per kg. of body weight per day of N,N-methylene-bis-(3-bromopropionamide).
  • a method for causing the remisison of tumors in mammals which comprises administering in dosage unit form from 5 mg. to 500 mg. per kg. of body weight per day of N,N-methylene-bis-(3-iodopropionamide) 8.
  • a method for causing the remission of tumors in mammals which comprises administering in dosage unit form from 5 mg. to 500 mg. per kg. of body weight per day of N,N-methylene-bis-(3-buteneamide).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

3,085,940 N,N-METHYLENE-BliS-AMTDES FUR THE SUPPRESSION F TUMORS Andrew S. Tonicnt'cilr, Tappan, N311, Stuart D. Willson,
Park Ridge, NJ., and Adolph W. Vogel, Peal River, N.Y., assignors to American Cyanarnid Company, New Yorl-i, N.Y., a corporation of Maine No Drawing. Filed May 9, 1960, Ser. No. 27,488 8 Claims. (Cl. 167--65) This invention relates to novel compositions of matter for the treatment of malignant growths in mammals.
In recent years there has been noted a greater incidence of tumor growth than heretofore. This has been ascribed. to various reasons including longer life span, the pressures of modern life, food additives, tobacco, etc. A need exists, therefore, for compositions which are destructive to tumorous cells while at the same time having comparatively little or no elfeet on normal cells. In the past many compositions have been tried including, for example, the nitrogen mustards and other chemicals. These compositions have not been very satisfactory because of undesirable and sometimes severe side eitects.
We have now discovered that compounds represented by the following general tormula, when the active ingredient of the novel compositions of matter of the present invention, are useful in causing the remission oftumors R;( JNH-CHiNI-I( B in which R and R are the same and are selected from the group consisting of the allyl and 2-haloethyl radicals. The most efiective compounds in causing the remission of tumors are those according to the above general for mula wherein R and R are the same and are selected from the group consisting of the allyl, 2-bromoethyl, and 2-iodoethyl radicals.
The compounds of the present invention may be readily prepared by the interaction of 2 moleslof B-buteneamide or 2 moles of the appropriate '3-halopropionamide with 1 mole of formalhyde in the presence of a strong acid. Ordinarily, the reaction is carried out for a period of time ranging from a 'few minutes to an hour or more and at a temperature ranging from 30 C. to 100 C. Alternatively, the appropriate nitrile may be substituted for the 3-buteneamide or 3-halopropionamide as the starting material. In such case, hydrolytic conditions are employed so that the nitrile is hydrolyzed to its corresponding amide. Furthermore, alternate forms of formaldehyde such as paraformaldehyde may also be used. Generally, the desired product may then be recovered from the reaction mixture by concentration or by dilution with water.
The compounds of the present invention were tested against the tumors Sarcoma 180, lymphosarcoma 6C HED and C H mammary adencarinoma 72 Tumors from donor mice were minced and the particles transplanted, using a trocar, and inserted subcutaneously into the axillary region of a C l-I inbred strain of mice. When the tumors had grown to a palpable size (5-14 days) depending on the particular tumor, the test mice were grouped according to tumor size and treatment was started. An exception was the lymphosarcoma 6C HED in which treatment was started 2 to 3 days after implant before tumors were palpable. Treatment was by daily intraperitoneal injection for 6 days. Tumor harvest was on the seventh day following the first treatment. The tumors were weighed after excision and the following activity ratio was determined.
3,085,940 Patented Apr. 16, 1963 Activity ratio Average Weight oftumors from control mice -Average weight of tumors from treated mice A compound was judged active if its activity ratio exceeded 3.50in the case of Sarcoma 180, 6.39 in the case of lymphosarcoma 6C HED, and 3.72 in the case of adenocarcinoma 72j..
The following table summarizes the testing results for The dosage of the compounds of the present invention differs according to the compound, and the progression of the disease. The oral dose per day may vary from 5 to 500 mg. per kg. of body weight. A divided dose may vary from 50 mg. to 5.0 g. and the frequency of administration may vary widely.
The activity of the compounds of the present inventionagainst animal tumors presages a usefulness in the clinical remission of lymphomas and leukemia-s for periods of time that will vary with -difierent individuals. However, the effectiveness o-tthe compounds of the present inven: tion in causing the remission of tumors in human subjects has not yet been demonstrated.
The compounds of the present invention may be orally administered in any. of the usual dosage unit forms of pharmaceutical preparations. These may take the form of tablets, capsules, pills, powders orany other desirable form in the therapeutic quantities set forth above. The dosage form may be for a single daily therapeutic dose or in smaller units for multiple doses or in larger units for division into single doses. It is understood that in addition to the therapeutic compound there may be present excipients, binders, fillers, and other therapeutically inert ingredients necessary in the formulation of pharmaceutical preparations.
The compounds of the present invention may also be administered parenterally by dissolving or suspending the compound in a parenterally suitable vehicle such as, for example, propylene glycol or polyethylene glycol, or by dissolving or suspending the compound in an aqueous solution of such vehicle.
The following examples show the preparation and formulation of the therapeutic compounds of the present invention.
Example 1 N, N'-METHYLENE-BIS-(s-BROMOPROPIONAMIDE) A solution of 8.3 g. of 37% tormaldehyde in 21 g. of concentrated sulfuric acid was added to 26.8 g. of 3- bromopropionit-rile at 35-40 C. After five hours the solution was poured onto ice and the crude product was removed by filtration. There was obtained 25 .0 g. (79% crude yield) of N,N-methylene-bis-(3-bromopropionamide). M.P. 184-186.5 C. Recrystallization from 80% acetone gave white crystals, M.P. 184.5-1-86.5 C.
3 Example 2 N,N -i\HETHYLENE-BIS- 3-IODOPROPIONA1MIDE) A mixture of 10.0 g. of 3-iodopropionamide, 0.75 g. of paraformaldehyde, and 0.8 ml. of concentrated hydrochloric acid in 150 ml. of ethylene dichloride was refluxed for minutes. There was obtained 9.4 g. (91% crude yield) of N,N-methylene-bis-(3-iodopropionamide), M.P. 191-193 C. dec. Recrystallization from 90% isopropyl alcohol gave 8.6 g. of white crystals, M.P. 193l94 C. dec.
Example 3 N,N' -METHYLENE-BIS- 3-BUTENEAMIDE) A solution of 8.1 g. of 37% formaldehyde in 21 g. of concentrated sulfuric acid was added dropwise to 13.4 g. of 3-butenenitrile at 15 C. The resulting thick syrup was stored overnight at 25 C. and then poured onto ice. The crude product was removed by filtration whereby there was obtained 10.7 g. (58% crude yield) of N,N'- methylene-bis-(3-buteneamide), M.P. 193-198 C. After recrystallization from 95% ethanol, there was obtained 8.6 g. of white crystals, M.P. 198199 C.
Example 4 A mixture of parts of N,N-methylene bis-(3- bromopropionamide), 15 parts of starch, and 1 part of magnesium stearate was thoroughly blended and then screened through a 60 mesh screen. The resulting powder was tableted in an automatic tableting machine whereby suitable 500 mg. scored white tablets were obtained.
What is claimed is:
1. A therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to 50 g. of a compound having the general formula 0 R.( i-NHoHr-NH- iRl wherein R and R are the same and are selected from the group consisting of the allyl and 2-haloethyl radicals, and a solid pharmaceutical carrier.
2. A therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to 50 g. of N,N-methylene-bis- (3-bromopropionamide) and a solid pharmaceutical carrier.
3. A therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to g. of N,N'-methylene-bis- (3-iodopropionamide) and a solid pharmaceutical carrier.
4. A therapeutic composition for oral administration useful for the remission of tumors in dosage unit form comprising from 0.25 g. to 50 g. of N,N'-methylene-bis- (3-butenearnide) and a solid pharmaceutical carrier.
5. A method for causing the remission of tumors in mammals which comprises administering in dosage unit form from 5 mg. to 500 mg. per kg. of body weight per day of a compound of the formula:
R1 iNH-0HzNH-( i-R2 wherein R and R are the same and are selected from the group consisting of the allyl and 2-haloethyl radicals.
6. A method for causing the remission of tumors in mammals which comprises administering in dosage unit form 'from 5 mg. to 500 mg. per kg. of body weight per day of N,N-methylene-bis-(3-bromopropionamide).
7. A method for causing the remisison of tumors in mammals which comprises administering in dosage unit form from 5 mg. to 500 mg. per kg. of body weight per day of N,N-methylene-bis-(3-iodopropionamide) 8. A method for causing the remission of tumors in mammals which comprises administering in dosage unit form from 5 mg. to 500 mg. per kg. of body weight per day of N,N-methylene-bis-(3-buteneamide).
References Cited in the file of this patent UNITED STATES PATENTS 2,475,846 Lundberg July 12, 1949 FOREIGN PATENTS 743,466 Germany Nov. 4, 1952 OTHER REFERENCES Pfizer Spectrum, Screening of Anti-Cancer Agents, vol. 7, No. 3, March 1959, pp. 62-63.
American Jurisprudence-Proof of Facts, Annotated, vol. 3, Brakes to Damages, 1959 by Jurisprudence Publishers, Inc., The Lawyers Co-operative Publishing Co., Rochester, N.Y., Cancer, pp. -131.

Claims (1)

1. A THERAPEUTIC COMPOSITION FOR ORAL ADMINISTRATION USEFUL FOR THE REMISSION OF TUMORS IN DOSAGE UNIT FORM COMPRISING FROM 0,25 G. TO 50 G. OF A COMPOUND HAVING THE GENERAL FORMULA
US27488A 1960-05-09 1960-05-09 Nu, nu'-methylene-bis-amides for the suppression of tumors Expired - Lifetime US3085940A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US27488A US3085940A (en) 1960-05-09 1960-05-09 Nu, nu'-methylene-bis-amides for the suppression of tumors
FR847668A FR1202M (en) 1960-05-09 1960-12-22 Amide compositions.
GB44723/60A GB905186A (en) 1960-05-09 1960-12-30 Pharmaceutical compositions for the treatment of malignant growths comprising amides
BE598856A BE598856A (en) 1960-05-09 1961-01-05 Amide compositions.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27488A US3085940A (en) 1960-05-09 1960-05-09 Nu, nu'-methylene-bis-amides for the suppression of tumors

Publications (1)

Publication Number Publication Date
US3085940A true US3085940A (en) 1963-04-16

Family

ID=21838021

Family Applications (1)

Application Number Title Priority Date Filing Date
US27488A Expired - Lifetime US3085940A (en) 1960-05-09 1960-05-09 Nu, nu'-methylene-bis-amides for the suppression of tumors

Country Status (1)

Country Link
US (1) US3085940A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3157567A (en) * 1962-09-12 1964-11-17 Us Rubber Co Fungicides
US3300476A (en) * 1963-05-24 1967-01-24 Mack Chem Pharm Deoxyribonuclease blocking agents
US4146646A (en) * 1976-02-12 1979-03-27 Fisons Limited Bis-amide fungicidal compounds
US5068240A (en) * 1983-12-20 1991-11-26 Adam Kovacs Antitumor pharmaceutical compositions and process for preparing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2475846A (en) * 1946-10-31 1949-07-12 American Cyanamid Co Alkylidene-bis-acrylamides
DE743466C (en) * 1939-05-11 1952-11-04 I G Farbenindustrie A G Frankf Process for the production of diacrylic acid diamides and their polymerization products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE743466C (en) * 1939-05-11 1952-11-04 I G Farbenindustrie A G Frankf Process for the production of diacrylic acid diamides and their polymerization products
US2475846A (en) * 1946-10-31 1949-07-12 American Cyanamid Co Alkylidene-bis-acrylamides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3157567A (en) * 1962-09-12 1964-11-17 Us Rubber Co Fungicides
US3300476A (en) * 1963-05-24 1967-01-24 Mack Chem Pharm Deoxyribonuclease blocking agents
US4146646A (en) * 1976-02-12 1979-03-27 Fisons Limited Bis-amide fungicidal compounds
US5068240A (en) * 1983-12-20 1991-11-26 Adam Kovacs Antitumor pharmaceutical compositions and process for preparing the same

Similar Documents

Publication Publication Date Title
US3047461A (en) Central nervous system stimulant
US20080108706A1 (en) Chemical resection of pancreas
US3085940A (en) Nu, nu'-methylene-bis-amides for the suppression of tumors
DE2923009A1 (en) AGENT FOR PROPHYLAXIS AND TREATMENT OF FIBROSE
US3483221A (en) 1 - (isopropylamino)-2-hydroxy-3-(alkenyloxyphenoxy) - propanes and the salts thereof
US4180588A (en) Immunosuppressant
US3051625A (en) Dithiocarbamate tumor-inhibitory process
US3085941A (en) Acrylamide derivatives for the suppression of tumors
FR2620450A1 (en) NOVEL SALTS OF ORGANOGERMANIC COMPOUNDS AND MEDICAMENTS CONTAINING SAME
US4673690A (en) Acylated enamides and pharmaceutical compositions containing them
US3210247A (en) Anti-epileptic i-cyclohexyl-z-methyl- aiviino propane salt of phenyl ethyl barbituric acid
US3988461A (en) Pharmaceutical composition for the treatment of Parkinson's disease
SU827489A1 (en) N'-d,1-alpha-tocopheryl-carbonyl-5-fluorouracyl possessing antitumor activity
US3332975A (en) Mono-and di-substituted ureas
FR2490092A1 (en) NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON 1,4-DIHYDROPYRIDINE DERIVATIVE
US3169091A (en) Process for inhibiting tumors with substituted pyrazoles
US3969532A (en) 1-Aryl-3-(2-hydroxyethyl) thioureas for treating depression
US3067242A (en) Di-(n, n-dimethyloctadecylamine) pamoate
US3928590A (en) Ortho-mercaptoaroylamides and salts thereof as hypoglycemic agents
US3463861A (en) Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols
US3975433A (en) 1-(2,4-Dimethoxy-phenyl)-3-(2-hydroxyethyl)thiourea
JPS63264580A (en) 3-(2-haloalkyl)-1,4-oxathiin and 2-(2- haloalkyl)-1,4-dithiin
AU627748B2 (en) Novel selenious acid-platinum complex and anti-tumor agent comprising said complex as effective ingredient
US4423076A (en) 1-Branched-alkyl-3-(2-haloethyl)-3-nitrosoureas as novel antitumor agents
US3891769A (en) Psychotherapeutic methods employing thioureas